GRAIL/$GRAL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
- Ticker
- $GRAL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 910
- Headquarters
- Menlo Park, United States
- Website
- grail.com
GRAIL Metrics
BasicAdvanced
$7.1B
-
-$9.75
3.25
-
Price and volume
Market cap
$7.1B
Beta
3.25
52-week high
$166.48
52-week low
$41.50
Average daily volume
1.4M
Financial strength
Current ratio
10.949
Quick ratio
10.55
Long term debt to equity
0.032
Total debt to equity
0.036
Profitability
EBITDA (TTM)
-378.489
Gross margin (TTM)
49.71%
Net profit margin (TTM)
-236.95%
Operating margin (TTM)
-323.04%
Effective tax rate (TTM)
26.04%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-12.03%
Return on equity (TTM)
-16.12%
Valuation
Price to revenue (TTM)
38.374
Price to book
2.77
Price to tangible book (TTM)
9.26
Price to free cash flow (TTM)
-21.413
Free cash flow yield (TTM)
-4.67%
Free cash flow per share (TTM)
-7.373
Growth
Revenue change (TTM)
23.07%
Earnings per share change (TTM)
-25.39%
What the Analysts think about GRAIL
Analyst ratings (Buy, Hold, Sell) for GRAIL stock.
Analyst projections of the future price of GRAIL stock.
Bulls say / Bears say
The FDA advisory panel voted that Galleri’s benefits outweigh its risks, a key step towards approval that could open a path to broader access and Medicare coverage from 2028. The FDA still has the final say. (Reuters)
Galleri sales are gaining pace: second-quarter test volume rose 35% year on year and screening revenue increased 24%. A new employer-group arrangement with Priority Health and planned Epic integration could help widen access. (GRAIL)
Although the NHS-Galleri trial missed its main endpoint, later screening rounds showed fewer Stage IV diagnoses, while adding the test increased screen-detected cancers. If these secondary findings translate into better outcomes, they could support Galleri’s clinical case. (GRAIL)
The large NHS-Galleri trial did not meet its primary goal of reducing combined late-stage cancers. There is still no evidence that Galleri screening reduces cancer deaths, leaving its ultimate clinical benefit unproven. (The Lancet)
FDA approval would not guarantee reimbursement: most private insurers and government programmes do not currently cover multi-cancer tests, so many patients must pay out of pocket. Wider adoption will depend on payers accepting the test’s value and price. (Reuters)
GRAIL remains deeply loss-making, with a $110 million net loss in the second quarter and $168 million of operating cash used in the first half of 2026. The company expects operating losses to continue for several years, despite its cash and securities reserve. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
GRAIL Financial Performance
Revenues and expenses
GRAIL Earnings Performance
Company profitability
Upcoming events
No upcoming events
GRAIL News
AllArticlesVideos
Funds containing GRAIL
Fund name | Fund size | $GRAL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.62% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.62% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.62% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.45% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.45% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.